Coronavirus Reveals the Recklessness of Drug Pricing Reform


By Stacy Washington

A Seattle patient recently became the first American to receive a potential breakthrough vaccine for COVID-19. That vaccine -- developed by Moderna, a Massachusetts biotech start-up -- is one of several experimental coronavirus vaccines and treatments that pharmaceutical firms are developing around the country.

The industry's lightning-fast reaction is a testament to the ingenuity of America's scientists and the dynamism of America's drug-development system. And it's a reminder that Washington's ongoing effort to defund pharmaceutical innovation puts millions of lives at risk.

To say that drug firms have moved quickly to combat this pandemic is an understatement. In the nearly three months since the first case of COVID-19 made headlines, drug companies across the country have snapped into action.

Many companies have promising therapies in the pipeline. In addition to Moderna, Pennsylvania-based Inovio and Johnson & Johnson have potential vaccines. Remdesivir, an antiviral from Gilead Sciences that has shown promise against the novel coronavirus, has undergone multiple clinical trials.

While impressive, the breakneck response of American research firms isn't completely surprising. After all, America does pharmaceutical innovation better than any other country.

The United States develops two-thirds of the world's new drugs. In the last ten years, American drug firms have spent over half a trillion dollars on research and development -- more than the private investments of all other countries combined.

Our unrivaled research infrastructure naturally puts the American pharmaceutical sector in the best position to address an emergency like COVID-19.

Americans should be proud of our nation's prowess in life-sciences research. Yet, for the past several years, many in Washington have sought to destroy the market incentives that undergird the country's drug-innovation ecosystem.

A bill introduced last year by Senators Chuck Grassley (R-Iowa) and Ron Wyden (D-Oregon), for instance, would fine drug companies that increase the price of certain drugs covered by Medicare Part D faster than the rate of inflation.

These policies amount to government-imposed price controls -- precisely the sorts of market interventions that have hamstrung drug development in places like Germany, France, and the United Kingdom.

Before the widespread adoption of price controls, Europe was a drug development juggernaut. In the 1970s, those three countries alone combined to produce 45 percent of new therapies invented worldwide. From 2001 to 2010, they produced just 20 percent. Our country develops the most new drugs today because we maintained a free market for prescription medicines.

Companies undertake tremendous risk when developing drugs. On average, developing just one medicine takes more than a decade and costs over $2.5 billion after accounting for all of the medicines that don't pan out.

Investors will tolerate that risk because, in the United States, drug companies can sell their products at a fair market price.

But the economic logic of drug development vanishes if the government can simply dictate whatever price it deems appropriate.

If any of the price-control reforms on the table took effect, private investment in medical research would quickly flee to less risky ventures. From there, it wouldn't take long for the world's most powerful engine of drug discovery to break down.

A collapse in medical innovation would be harmful in the best of times. But during a global-health emergency like the COVID-19 pandemic -- a moment that demands the full force of America's biotech ingenuity -- it would be nothing short of calamitous.

Stacy Washington is a decorated Air Force Veteran, an Emmy nominated TV personality, and the host of the nationally syndicated radio program "Stacy on the Right."

More Resources


03/27/2024
Biden, Trump Know RFK Jr.'s VP Choice a Game Changer


more info


03/27/2024
Republican 'War on Women' Is a Media Myth
There's no evidence Republicans want to ban birth control. On the contrary, the GOP has led on efforts to make it easier to get birth control over the counter.

more info


03/27/2024
Supreme Court Scoffs at Flimsy Abortion Pill Argument


more info


03/27/2024
NBC's Failed Attempt To Appeal to MAGA Voters
I spent years in the MAGA cult: We loathed Ronna Romney McDaniel almost as much as we loathed the media

more info


03/27/2024
Democrats Are Better for the US Economy
Jeffrey Frankel notes that this is no mere correlation, though the cause remains an enduring puzzle.

more info


03/27/2024
TikTok's Dangerous Influence Over Kids
Congressional talk about TikTok needs to be a wake-up call to parents. The Chinese app exposes kids to dangerous content, especially about suicide. It's 'every parents's nightmare.'

more info


03/27/2024
Smartphones Rewired Childhood. Here's How to Fix It.
Phones have made kids sedentary, solitary, anxious, and depressed. But, says the author and psychologist, we can reverse the damage.

more info


03/27/2024
NBC Cements Status as Anti-Trump, Pro-Biden Network
The dramatic saga following NBC's announced hire of former RNC chair Ronna McDaniel solidified the network's position as being fully anti-Trump going into the 2024 election.

more info


03/27/2024
Don't Tell This 'Double-Hater' She's Crazy
Most of those known as 'double haters' will come around to support one of the two major party presidential nominees. But some, like Victoria Thompson, won't back Trump or Biden under any circumstances.

more info


03/27/2024
Joe Biden, the (Still) Unpopular President
There's been a lot of wishful reporting about the political fortunes and reelection hopes of President Joe Biden.

more info


03/27/2024
Trump's Crumbling Empire Gives Biden a Golden Opportunity
Here's a phrase I never thought I'd say: Donald Trump, Bible salesman.

more info


03/27/2024
Democrats Distort the Law To Subvert 2024 Election
An appeals court just gutted New York's $454 million fine against Trump in ‘a fraud case in which there are no fraud victims.'

more info


03/27/2024
RFK Jr. Makes New Play for Disaffected w/Nicole Shanahan
Mr. Kennedy's allies hope his choice of a wealthy Silicon Valley lawyer to be his running mate will inject new energy and financial support into his independent bid for the White House.

more info


03/27/2024
SCOTUS Must Rely on 1st Amendment Censorship Case
The justices of the Supreme Court never focused on the First Amendment's words when hearing arguments in Murthy v. Missouri last week. The case challenges the federal government's orchestration of social media censorship, so one might have expected the justices to pay some attention to the First Amendment itself.

more info


03/27/2024
The Republican House Fails the Ronald Reagan Test
Following its Friday failure to deliver a new package of aid for Ukraine, it's time for a title change in the US House of Representatives.

more info



Custom Search

More Politics Articles:

Related Articles

Get Ready for an American Energy Comeback


Judging from the headlines, America's energy sector could collapse at any moment. Scattered amidst coronavirus coverage are reports of plummeting energy stocks and commodities traders paying people to take barrels of oil off their hands.

Trump Administration Should Reject Foreign Prescription Drug Price Controls


In responding to the coronavirus pandemic, President Trump has rightly focused on the tremendous innovative capacity of American businesses -- first by waiving regulations that impose unnecessary burdens, next by providing incentives to get tough jobs such as vaccine development done as quickly as possible.

Clearing the Air on the EPA's Coronavirus Response


The Environmental Protection Agency (EPA) agency recently issued a memo waiving certain compliance requirements for energy firms in light of the COVID-19 outbreak. A group of House Democrats falsely claimed the EPA's memo gives oil and gas companies an "open license to pollute." To address lawmakers' concerns, the EPA has tapped an internal watchdog to review the policy. But no matter how hard they look, the investigators won't find anything close to what Democrats have suggested.

If Trump is Not Reelected, America Will Be Hurting


Most every American has an opinion about the upcoming election. However, there are several realities we must face.

For Workers' Sake, Keep the Pressure on America's Trading Partners


In his marathon testimony before Congress earlier this summer, United States Trade Representative Robert Lighthizer detailed the trade-policy achievements of President Trump's first term. It's a list that should make the administration proud.

Superbugs will Kill Millions — Unless Congress Acts


We're in the midst of the worst health crisis of the 21st century -- and it's not COVID.

Why Do We Take to the Streets?


We Americans are quick to take our disagreements to the streets. In 2020, we have claimed many causes to do so. Millions came out to protest police violence and “resist” fascism. Others “rallied” against COVID-19 lockdowns and voter fraud. We may amass crowds to evoke sympathy or provoke debate. But demonstrations aggravate and intimidate, often drawing counter protesters if not ending in violence. And even when gatherings generate debate, we are tempted to settle them by who had the larger crowd size rather than the merits of the case.

Biden Administration Must Commit to a National Pandemic Preparedness Strategy


COVID-19 has killed more than 350,000 Americans. And with case counts and hospitalizations soaring, many more deaths are sadly in store.

The FDA Can Help Patients With Rare Diseases


When I was just 18 years old, I was diagnosed with hypoparathyroidism, a rare disease that causes seizures, extreme fatigue and other life-altering complications.

A Simple Fix for Biden to Help to Make Drugs More Affordable


Americans have problems affording many drugs at pharmacies and doctors' offices. About half of those who are sick have trouble paying for their medications, according to a recent poll from the Kaiser Family Foundation.

America is Ready For a Resurrection


The followers of Jesus believed in his resurrection because they saw him alive after he was dead. They had a powerful testimony of firsthand evidence seen with their own eyes.

Small Changes to 340B Can Make a Big Difference for Struggling Patients


The Covid-19 pandemic has made the issue of healthcare access more urgent than ever. Yet, at a time of deep divisions in Washington, chances for major reform are slim.

The Need for Reconciliation is a Sign of a Bad Bill


"Budget Reconciliation" may be the most popular phrase on Capitol Hill right now. This special legislative process allows certain bills to be passed in the Senate with a simple majority so long as they impact the budget.

America was Prepared to Fight Covid-19 Thanks to Intellectual Property Rights


When Covid-19 came ashore, glaring gaps in the government's pandemic preparedness became painfully obvious. Everything from inadequate stockpiles of personal protective equipment to confusing and uncoordinated guidance regarding closures hampered our early response.

Democrats Chose the Worst Time to Revive Medicare for All


Medicare for All just won't die. More than 100 House Democrats have signed onto new legislation that would outlaw all private insurance and put all Americans on a federally-run insurance plan within two years.